MASSDEVICE ON CALL — Surviving sudden cardiac arrest depends largely on the people around you and easy access to an automated defibrillator, or AED. It turns out that the gym is the best indoor location for cardiac arrest victims’ survival chances, likely because of the increased presence of AEDs and well-placed instruction manuals.
Cardiovascular
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
Latest Cardiology News
W.L. Gore claims win in patent war with St. Jude Medical
W.L. Gore & Assoc. claimed a win in its patent war with St. Jude Medical (NYSE:STJ) over heart defect repair technology, after a federal judge in Minnesota dismissed the suit.
Labeling glitch with Boston Scientific’s Promus Element Plus prompts recall in Australia
Boston Scientific (NYSE:BSX) shipped some of its Promus Element Plus Monorail coronary stents with the wrong labels in Australia, prompting that country’s Therapeutic Goods Administration to issue a recall.
Medtech poster children: Bush follows Cheney with a cardiac stent | MassDevice.com On Call
MASSDEVICE ON CALL — Former President George W. Bush followed in the footsteps of his VP, going under the knife to receive an implanted stent to clear blockage in an artery 13 years after Dick Cheney.
A spokesman for the former President did not reveal which stent-maker developed the product now safely clearing the president’s blockage, but his and other public figures’ medical procedures sometimes have the power of an unintended celebrity endorsement.
TAVI: Edwards wins FDA approval to begin clinical studies of next-gen Sapien 3 valve
Cardiologist must cough up $17M in false Medicare billing case
A Washington, D.C., cardiologist was hit with a $17 million judgment after being found guilty of submitting false claims for nuclear imaging tests to Medicare and state health programs.
AtriCure, still in the red, beats Wall Street’s Q2 forecast
A penny spent is a penny earned in Canadian heart research | MassDevice.com On Call
MASSDEVICE ON CALL — An Canadian study of the return on investment in heart research found that for every $1 spent on cardiovascular research, the nation sees a 21% income stream.
Heart research in Canada is mostly funded by the government and by nonprofit organizations in the Great White North.
Sign up to get our free newsletters delivered straight to your inbox
[sead]
Sex after a heart attack – docs issue official guide | MassDevice.com On Call
MASSDEVICE ON CALL — Heart attack and stroke patients now have access to the 1st detailed clinical guidelines on safely re-igniting their love lives after a cardiac event.
In a joint statement the American Heart Assn. and the European Society of Cardiology published a detailed "how-to" guide for cardiac patients and their doctors, offering recommendations of when and how a patient should resume sex.
20% of cardiac ultrasounds have little impact on patient care | MassDevice.com On Call
MASSDEVICE ON CALL — 1 out of every 5 cardiac ultrasounds given to patients may be in vain, according to a new study. Although not disparaging use of cardiac ultrasound, researchers concluded that about 20% of the imaging tests had little impact on future patient treatment.
For doctors who needs more information, this heart imaging technique, called transthoracic echocardiogram, can often be the right call, but the study also found that for 50% of patients merely see a "continuation" of treatment following the evaluation.
Q2 profits surge for Edwards Lifesciences
Edwards Lifesciences (NYSE:EW) posted surging 2nd-quarter profits on modest sales growth, saying sales of its flagship Sapien heart valve reached $90 million for the quarter.